Andrassy K, Ritz E
Curr Probl Clin Biochem. 1979(9):330-41.
Physico-chemical characteristics of urokinase in urine were studied by immunological and chemical methods. By agar zone electrophoresis, commercial urokinase preparations could be separated into an anodic and cathodic fraction. The latter reacted with urokinase antibodies with two precipitation bands. Band I displayed the major part of urokinase activity and migrated as a beta-globulin with a molecular weight of 32,000 daltons. Band II showed immunological identity with human serum, human albumin, alpha-2-macroglobulin and alpha-2-HS-glycoprotein. The specific activity of the cathodic fractions was up to 80,000 ploug units/mg protein. The ratio esterase/fibrinolytic activity did not change during the purification procedure. Further purification of the fractions with higher specific activity by affinity chromatography was unable to eliminate material cross reacting with human antisera (Band II). These findings permit the conclusion, that urokinase activity in urine is not confined to a homogeneous protein fraction. Activity is found both in a low molecular weight fraction and in a high molecular weight complex which contains serum proteins. These cannot be removed by exhaustive purification procedures and may play an important role in stabilizing and/or protecting urinary urokinase against proteolytic degradation. With Todd's technique diffuse fibrinolytic activity could be demonstrated in the kidney in the iuxtamedullary border region, (venae arcuatae, venae interlobulares, vasa recta) and in the epithelium of the calyces. Urokinase activity was specifically blocked by highly purified urokinase antibodies and could thus be distinguished from nonspecific proteolytic activity. The topographic relationship to medulla and uroepithelium may point to a role of urokinase in maintaining patency in slow flow systems.
采用免疫学和化学方法研究了尿液中尿激酶的理化特性。通过琼脂区带电泳,市售尿激酶制剂可分离为阳极和阴极组分。后者与尿激酶抗体反应产生两条沉淀带。带I显示了尿激酶活性的主要部分,迁移时表现为一种分子量为32000道尔顿的β球蛋白。带II与人血清、人白蛋白、α-2-巨球蛋白和α-2-HS-糖蛋白具有免疫同一性。阴极组分的比活性高达80000普洛格单位/毫克蛋白质。在纯化过程中,酯酶/纤维蛋白溶解活性的比值没有变化。通过亲和层析进一步纯化比活性较高的组分,无法消除与人类抗血清反应的物质(带II)。这些发现可以得出结论,尿液中的尿激酶活性并不局限于单一的蛋白质组分。在低分子量组分和含有血清蛋白的高分子量复合物中均发现了活性。这些物质不能通过彻底的纯化程序去除,可能在稳定和/或保护尿中尿激酶免受蛋白水解降解方面发挥重要作用。用托德技术可在肾脏的髓旁边界区域(弓形静脉、小叶间静脉、直小血管)和肾盂上皮中显示出弥漫性纤维蛋白溶解活性。尿激酶活性可被高度纯化的尿激酶抗体特异性阻断,因此可与非特异性蛋白水解活性区分开来。与髓质和尿上皮的地形关系可能表明尿激酶在维持慢流系统通畅方面的作用。